• Receipts from customers increased by 28% to $1.6 million
• Cash outflows from operating activities improved by $2.0 million
• Cash and cash equivalents at $4.9 million as of March 31, 2025

Universal Biosensors, Inc. (ASX:UBI) has released its cash flow report (ASX Appendix 4C) and quarterly activity report for the quarter ended 31 March 2025 (Q1 2025). Key developments during the quarter include:- Receipts from customers increased by 28% to $1.6 million when compared to the same period in the previous year (Q1 2024)- Cash outflows from operating activities improved by $2.0 million when compared to Q1 2024- Cash and cash equivalents including restricted cash as at 31 March 2025 was $4.9 million- Payments of $91,262 were made for non-executive directors' fees, allowances and superannuationUniversal Biosensors is a world leader in electrochemical cell technology, having developed portable, handheld, high-performance liquid testing products for use in different markets, including blood testing, wine testing, veterinary testing, and water testing. The company is now focused on commercialisation and driving significant sales growth across all markets.

The company expects operating cashflows to improve significantly following the appointment of new sales resources in 2024, remediation of product failures in 2024, the achievement of FDA product approval in the USA for Xprecia in 2024, signing major distribution agreements for Xprecia in Q4 2024, and the launch of a new product offering in Q4 2025, Aquascout (testing heavy metals in water).

Universal Biosensors is in discussions with various interested stakeholders to raise further cash to fund its operations, and the likelihood of success is high. The company expects to be able to continue its operations and meet its business objectives based on the expected improvements in operating cashflows and the likelihood of securing additional funding.